Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies
Open Access

Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status

TOMOHITO MAEDA, HIROTAKA KONISHI, WATARU TAKAKI, KAZUYA TAKABATAKE, DAIKI MATSUBARA, KATSUTOSHI SHODA, TOMOHIRO ARITA, HIROKI SHIMIZU, SHUHEI KOMATSU, ATSUSHI SHIOZAKI, YOSHIAKI KURIU and EIGO OTSUJI
Anticancer Research April 2021, 41 (4) 1761-1769; DOI: https://doi.org/10.21873/anticanres.14941
TOMOHITO MAEDA
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROTAKA KONISHI
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: h-koni7@koto.kpu-m.ac.jp
WATARU TAKAKI
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAZUYA TAKABATAKE
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DAIKI MATSUBARA
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUTOSHI SHODA
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOHIRO ARITA
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROKI SHIMIZU
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUHEI KOMATSU
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ATSUSHI SHIOZAKI
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIAKI KURIU
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EIGO OTSUJI
Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Clinical significance of plasma urothelial carcinoma associated 1 (UCA1) in patients with colorectal cancer (CRC) remains unclear. This study investigated the usefulness of plasma UCA1 as a biomarker in patients with CRC. Materials and Methods: UCA1 levels were measured in the plasma and tissue from patients with CRC by quantitative polymerase chain reaction. Relationships between plasma UCA1 and clinicopathological features were examined. Results: Plasma UCA1 levels were significantly lower in patients with CRC than in healthy volunteers. UCA1 expression in B-Raf proto-oncogene serine/threonine kinase (BRAF)-mutant CRC tissue was also lower than that in non-cancerous tissue, although it was higher in CRC with wild-type BRAF. In right-sided CRC, a lower plasma UCA1 level was associated with pT4 and BRAF mutation. In contrast, in left-sided CRC, higher plasma UCA1 was associated with pT4 and pStage 3b-4. Conclusion: Plasma UCA1 is a useful biomarker for CRC detection and predicting clinicopathological features, particularly BRAF mutation.

Key Words:
  • UCA1
  • colorectal cancer
  • BRAF mutation

Colorectal cancer (CRC) is the third most common cancer worldwide and has the second highest mortality rate (1). The cancer-related molecular mechanisms of CRC were recently elucidated, and less invasive surgical therapies followed by many drug therapies are now becoming available (2-4). Therefore, the number of CRC-related deaths may be reduced by early-stage diagnosis and the initiation of appropriate curative treatments. Moreover, the identification and elucidation of other novel molecular mechanisms of CRC will improve the prognosis of patients.

Long non-coding RNAs (lncRNAs) are of more than 200 nucleotides in length and classified as a family of non-protein-coding RNAs. They play a role in the development of various cancer types (5-10). Urothelial carcinoma-associated 1 (UCA1) is a lncRNA that was initially identified in bladder cancer (11), and its oncogenic roles and usefulness as a diagnostic marker have been confirmed (12, 13). Recent studies reported that UCA1 was up-regulated in CRC tissue, and high UCA1 expression in cancer tissue was associated with a poorer prognosis in patients with CRC (12-14).

Many non-coding RNAs, including lncRNAs, have been detected in the plasma of patients with cancer and identified as leading candidates for liquid biopsy (7, 15, 16). However, only a few studies have examined the level of circulating UCA1 in CRC. Therefore, the significance of the circulating UCA1 in relation to clinicopathological features and the prognosis remains unclear (7, 12-14).

In the present study, we examined the plasma UCA1 level in patients with CRC and investigated its relationship with clinicopathological features. UCA1 expression was also assessed in CRC tissue samples to clarify the relationship with the B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation status.

Materials and Methods

Patients and samples. Pre-operative plasma samples were collected from 76 patients with CRC who underwent radical resection of the primary lesion at Kyoto Prefectural University of Medicine between 2015 and 2019. Some patients with stage 4 disease had residual liver or lung metastasis after surgery. Twenty control samples were collected from healthy volunteers (HVs) who underwent surgery for non-cancer diseases, for example, inguinal hernia and cholelithiasis, under general anesthesia. Relevant clinical and survival data were available for all patients with CRC. Some paired cancer and non-cancerous mucosal samples were also collected from the surgically resected specimens of patients whose plasma UCA1 levels were examined.

Macro- and microscopic classifications of cancer were based on the ninth edition of the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma (17). In the present study, right-sided CRC consisted of cancer of the cecum and ascending and transverse colon up to the splenic flexure, while left-sided CRC comprised those of the descending and sigmoid colon and rectum.

Ethics statement. Ethical approval was granted by the Faculty of Science Ethics Committee at the Kyoto Prefectural University of Medicine, and the present study was conducted in accordance with the principles of the Declaration of Helsinki. Written informed consent on treatments and participation in the present study was obtained from all CRC patients and HVs.

Sample collection and storage. Blood samples were collected from patients with CRC and HVs in ethylenediaminetetra-acetic acid containing tubes (BD Vacutainer; Becton Dickinson and Company, Franklin Lakes, NJ, USA) before surgery under general anesthesia. They were immediately subjected to the preparation of plasma using a 3-spin protocol (350 × g for 30 min, 700 × g for 5 min, and 1600 × g for 5 min) to prevent contamination by cellular fractions. Plasma samples were stored at −80°C until further analyses.

RNA extraction. Total RNA was extracted from 400 μl of plasma samples using mirVana PARIS Kit (Ambion, Austin, TX, USA), and eluted into 100 μl of pre-heated (95°C) Elution Solution according to the manufacturer’s instructions. For tissue samples, total RNA was extracted from four 15-μm-thick formalin-fixed paraffin-embedded tissue slices (total thickness of 60 μm) using the RecoverAll Total Nucleic Acid Isolation Kit (Ambion). It was finally eluted into 60 μl of Elution Solution according to the manufacturer’s instructions. RNA samples were then stored at −80°C until further processing.

Detection of lncRNA by polymerase chain reaction (PCR). Reverse transcription reaction was performed using the High-Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster City, CA, USA). Nine microliters of total RNA extracted from 400 μl of plasma was used for this reaction. Regarding RNA extracted from tissue samples, the total RNA concentration was adjusted to 100 ng/μl, and the reverse transcription reaction was performed using 5 μl of RNA with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). These cDNA products were pre-amplified using the TaqPath qPCR Master Mix, CG (Applied Biosystems) and UCA1 primer of the human TaqMan Gene Expression Assay Kit (Assay ID: Hs05052446_gH; Applied Biosystems).

UCA1 levels were measured in duplicate by quantitative real-time PCR using the UCA1 primer following the manufacturer’s protocol. The quantitative PCR analysis was performed using the Step One Plus Real-time PCR system (Applied Biosystems), and cycle threshold (Ct) values were calculated with Step One Software version 2.2.2 (Applied Biosystems).

Plasma UCA1 levels were calculated using the ΔCt method relative to the plasma UCA1 level of one HV who underwent cholecystectomy for gallbladder stones and had no specific medication or previous history. UCA1 expression in tissue was normalized using the ΔΔCt method relative to the expression of glyceraldehyde-3-phosphate dehydrogenase (Assay ID: Hs02758991_g1; Applied Biosystems) in each sample. Finally, it was reported as a value relative to the expression in non-cancerous tissue of one patient with CRC (CRC160).

Confirmation of the BRAF mutation. In some cases, the BRAF gene V600E mutation status had already been analyzed. However, the mutation status of V600E was confirmed by focusing on cases of right-sided CRC using competitive allele-specific TaqMan PCR technology (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The BRAF_476_mu (Assay ID: Hs00000111_mu) probe with the corresponding wild-type allele assay BRAF_476_wt (Assay ID: Hs00000110_wt) and gene reference assay BRAF_rf (Assay ID: Hs00000172_rf; all from Applied Biosystems) were used in the Step One Plus Real-time PCR System (Thermo Fisher Scientific) following the manufacturer’s protocol.

Statistical analysis. The Mann–Whitney test or Student’s t-test was used to compare differences in the plasma UCA1 levels of unpaired samples or investigate relationships between plasma UCA1 levels and clinicopathological features. The paired t-test and Wilcoxon test were used to evaluate the significance of differences between cancer and non-cancer tissue samples. The median value of plasma UCA1 was used in the analysis of associations with clinicopathological features. A p-value of less than 0.05 was considered to be significant.

Results

Plasma UCA1 level and clinicopathological features. Plasma UCA1 levels were significantly lower in 76 patients with CRC than in 20 HVs (p=0.004, Figure 1A). Patient backgrounds are shown in Table I. There were 40 and 36 cases of right-sided and left-sided CRC, respectively. Relationships between the plasma UCA1 level and clinicopathological features in patients with CRC were examined by the median value of plasma UCA1. No correlations were found in the 76 cases examined (Table II). However, in right-sided CRC (Table III), a lower plasma UCA1 level was correlated with BRAF V600E mutation (p=0.048) and pT4 factor (p=0.048). On the other hand, in left-side CRC (Table IV), higher plasma UCA1 levels were correlated with pT4 factor (p=0.03) and pStage 3b-4 (p=0.01).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Plasma urothelial carcinoma associated 1 (UCA1) levels in patients with colorectal cancer (CRC). A: Plasma UCA1 levels were measured by quantitative real-time polymerase chain reaction in patients with CRC (n=76) and healthy volunteers (n=20). The relative UCA1 level is shown. B: The relative level of plasma UCA1 was compared among patients with B-Raf proto-oncogene serine/threonine kinase (BRAF)-mutant right-sided CRC (n=13), BRAF wild-type (wt) right-sided CRC (n=27), and left-sided CRC (n=40).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patient background characteristics (n=76).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Correlations between plasma urothelial carcinoma-associated 1 (UCA1) level and clinicopathological features in patients with colorectal cancer.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Clinicopathological features of patients with right-sided colorectal cancer according to plasma urothelial carcinoma-associated 1 (UCA1) level.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Clinicopathological features of patients with left-sided colorectal cancer according to plasma urothelial carcinoma-associated 1 (UCA1) level.

Relationship between plasma UCA1 level and the BRAF V600E mutation. The plasma UCA1 level was significantly lower in patients with BRAF-mutant right-sided CRC than in those with BRAF wild-type cancer (p=0.018), and did not significantly differ between patients with right- and left-sided BRAF wild-type CRC (p=0.325, Figure 1B).

UCA1 expression in CRC tissue. To clarify the impact of BRAF V600E mutation on UCA1 expression, UCA1 expression was examined in 26 paired cancer and non-cancerous tissue samples. The background characteristics of these 26 patients are shown in Table V. Eighteen patients with right-sided CRC were included, and BRAF V600E mutation was identified in nine patients.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Patient background analyzed in tissue sample (n=26).

UCA1 expression was significantly higher in cancer tissue than paired non-cancerous tissue (p=0.023, Figure 2A). These differences were observed in those with BRAF-wild-type right-sided CRC (p=0.033, Figure 2C) and left-sided CRC (p=0.009, Figure 2D). However, in BRAF-mutant right-sided CRC, UCA1 expression levels were slightly lower in cancer tissue, although not significantly (p=0.189, Figure 2B).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Urothelial carcinoma associated 1 (UCA1) expression in colorectal cancer (CRC) tissue. A: Relative UCA1 expression in cancer and paired non-cancer tissue is shown. B-D: Relative UCA1 expression in cancer and paired non-cancer tissue was compared among patients with B-Raf proto-oncogene serine/threonine kinase (BRAF)-mutant right-sided CRC (B, n=9), BRAF-wild-type (wt) right-sided CRC (C, n=9), and left-sided CRC (D, n=8). Upper and lower limits of the box plots and the line inside the boxes indicate the 75th and 25th percentiles and the median, respectively.

Discussion

UCA1 is strongly expressed in various cancer types (8, 18, 19), such as urinary bladder cancer (11), gastric cancer (20), hepatocellular carcinoma (21), esophageal cancer (22), pancreatic cancer (23), and CRC (12-14). Its overexpression was reported to be correlated with a poor prognosis (8, 19, 24). In CRC, higher UCA1 expression in tissue and cell lines was correlated with an advanced TNM stage, resistance to chemotherapies, and the progression of malignancies (12, 25-28).

In the present study, the plasma UCA1 level was significantly lower in patients with CRC than in HVs. They were especially lower in patients with BRAF-mutant right-sided CRC than in those with other CRC. Furthermore, UCA1 expression was slightly lower in BRAF-mutant right-sided CRC than the paired non-cancerous tissue, although it was significantly higher in BRAF wild-type CRC, regardless of side.

Previous studies reported that UCA1 expression was significantly higher in CRC tissue than in non-cancer tissue (12-14, 26). Our results are mostly consistent with these findings, but differed for those obtained for patients with BRAF-mutant right-sided CRC. The reasons for this difference need to be discussed; however, among the clinicopathological features of patients with CRC investigated in previous studies, the genomic or molecular status was not examined in detail. We are assuming that BRAF gene mutation affects UCA1 expression in CRC tissue. Furthermore, the plasma UCA1 levels in the present study may reflect the results obtained for UCA1 expression in CRC tissue.

Detailed molecular subtypes, including the CpG island methylator phenotype, microsatellite instability, chromosomal instability, and p53, KRAS, or BRAF mutation, have recently been reported (3, 30), and many differences in cancer progression and genomic or molecular status have been elucidated between right- and left-sided CRC (2, 4). In the present study, higher plasma UCA1 levels were associated with advanced cases in left-sided CRC (Table IV). This result is consistent with previous findings which showed that higher UCA1 expression in cancer tissue was associated with cancer progression and a poor prognosis (12, 13). On the other hand, in right-sided CRC, a lower plasma UCA1 level was associated with more advanced cases, and correlated with BRAF gene mutation (Table III). These differences between left- and right-sided CRC may be influenced by the mutation status of the BRAF gene.

The frequency of BRAF mutation in CRC was previously reported to be approximately 5-10%, with the most common type of BRAF-activating mutation being a valine to glutamine acid change at codon 600 (BRAF V600E) (29, 31). This BRAF mutation up-regulates the mitogen-activated protein kinase signaling pathway and plays essential roles in cellular proliferation, apoptosis, and survival (29-31). The BRAF mutation is generally mutually exclusive from KRAS mutations, and is clinically related to cancer progression, chemoresistance, and a poor prognosis, particularly in metastatic CRC (31). Confirmation of the BRAF mutation status before treatment is important because it is closely involved in treatment selection due to chemoresistance. Previous studies showed that the BRAF mutation status in primary CRC and matched metastatic lesions were in good concordance (31, 32). However, the sample sizes of previous studies were very small and discrepancies were also reported (33). Moreover, the effects of previous chemotherapy on the mutation status need to be considered. Therefore, particularly in patients with recurrence, the prediction of the BRAF mutation status by plasma UCA1 level would be useful as a liquid biopsy because tissue collection is often difficult in these patients.

In the present study, there are important issues that need to be resolved. The discrepancy between the lower plasma UCA1 level in patients with CRC and higher UCA1 expression in cancer tissue needs to be discussed. One important factor is BRAF gene mutation and reduced UCA1 level in cancer tissue and plasma. However, Barbagallo et al. showed that the UCA1 level in serum exosomes of patients with CRC was reduced compared with that of healthy controls, while the expression of UCA1 in CRC biopsy tissue was up-regulated relative to that in non-cancerous tissue (14). Therefore, other mechanisms may suppress the plasma UCA1 level. Furthermore, the reason why plasma and tissue UCA1 levels were lower in patients with BRAF gene mutation remains unclear. UCA1 expression is regulated by epigenetic and transcriptional factors, such as the direct binding of the transcription factor SP111 (34), or activation of the Hippo pathway (19). These factors need to be examined; however, we propose another possibility. Previous studies detected BRAF mutations in small polyps at early carcinogenesis (29, 30). In these tissues, the mitogen-activated protein kinase pathway will already be up-regulated by activating BRAF pathway, and, thus, UCA1 may not need to be up-regulated. This mechanism will also lead to mutually exclusive relationships between KRAS and BRAF mutations. In the future, these molecular mechanisms need to be investigated in more detail.

There are also some limitations of the present study. The small patient population and limited sample holding status prevent more general conclusions from being reached. Therefore, examinations of large-scale samples are needed. In tissue and plasma analyses, the frequency of the BRAF mutation was increased because we focused on its effects on UCA1 expression and selected samples with this mutation. Therefore, although it was not possible to examine clinicopathological features and prognosis in tissue samples according to UCA1 expression, plasma analyses of right- and left-sided CRC in the present study was warranted.

In conclusion, the plasma UCA1 level is a useful biomarker for the detection of patients with CRC and prediction of clinicopathological features. Moreover, it may predict BRAF gene mutation and facilitate treatment selection for patients with CRC.

Footnotes

  • Authors’ Contributions

    Maeda T, Konishi H, and Otsuji E were involved in study design and data interpretation. Maeda T, Konishi H, Takaki W, Takabatake K, Matsubara D, Shoda K, Arita T, Shimizu H, Komatsu S, Shiozaki A, and Kuriu Y were involved in the sample collection and the data analysis. All Authors revised the article and approved the submission.

  • This article is freely accessible online.

  • Conflicts of Interest

    The Authors declare no conflicts of interest for this study.

  • Received February 2, 2021.
  • Revision received February 16, 2021.
  • Accepted February 18, 2021.

This is an open access article distributed under the CC BY license (https://creativecommons.org/licenses/by/4.0/).

References

  1. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA and
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6): 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  2. ↵
    1. Lee GH,
    2. Malietzis G,
    3. Askari A,
    4. Bernardo D,
    5. Al-Hassi HO and
    6. Clark SK
    : Is right-sided colon cancer different to left-sided colorectal cancer? –A systematic review. Eur J Surg Oncol 41(3): 300-308, 2015. PMID: 25468456. DOI: 10.1016/j.ejso.2014.11.001
    OpenUrlCrossRef
  3. ↵
    1. Guinney J,
    2. Dienstmann R,
    3. Wang X,
    4. de Reyniès A,
    5. Schlicker A,
    6. Soneson C,
    7. Marisa L,
    8. Roepman P,
    9. Nyamundanda G,
    10. Angelino P,
    11. Bot BM,
    12. Morris JS,
    13. Simon IM,
    14. Gerster S,
    15. Fessler E,
    16. De Sousa E Melo F,
    17. Missiaglia E,
    18. Ramay H,
    19. Barras D,
    20. Homicsko K,
    21. Maru D,
    22. Manyam GC,
    23. Broom B,
    24. Boige V,
    25. Perez-Villamil B,
    26. Laderas T,
    27. Salazar R,
    28. Gray JW,
    29. Hanahan D,
    30. Tabernero J,
    31. Bernards R,
    32. Friend SH,
    33. Laurent-Puig P,
    34. Medema JP,
    35. Sadanandam A,
    36. Wessels L,
    37. Delorenzi M,
    38. Kopetz S,
    39. Vermeulen L and
    40. Tejpar S
    : The consensus molecular subtypes of colorectal cancer. Nat Med 21(11): 1350-1356, 2015. PMID: 26457759. DOI: 10.1038/nm.3967
    OpenUrlCrossRefPubMed
  4. ↵
    1. Iacopetta B
    : Are there two sides to colorectal cancer? Int J Cancer 101(5): 403-408, 2002. PMID: 12216066. DOI: 10.1002/ijc.10635
    OpenUrlCrossRefPubMed
  5. ↵
    1. Perez DS,
    2. Hoage TR,
    3. Pritchett JR,
    4. Ducharme-Smith AL,
    5. Halling ML,
    6. Ganapathiraju SC,
    7. Streng PS and
    8. Smith DI
    : Long, abundantly expressed non-coding transcripts are altered in cancer. Hum Mol Genet 17(5): 642-655, 2008. PMID: 18006640. DOI: 10.1093/hmg/ddm336
    OpenUrlCrossRefPubMed
    1. Silvia JM,
    2. Perez DS,
    3. Pritchett JR,
    4. Halling ML,
    5. Tang H and
    6. Smith DI
    : Identification of long stress-induced non-coding transcripts that have altered expression in cancer. Genomics 95(6): 355-362, 2010. PMID: 20214974. DOI: 10.1016/j.ygeno.2010.02.009
    OpenUrlCrossRefPubMed
  6. ↵
    1. Galamb O,
    2. Barták BK,
    3. Kalmár A,
    4. Nagy ZB,
    5. Szigeti KA,
    6. Tulassay Z,
    7. Igaz P and
    8. Molnár B
    : Diagnostic and prognostic potential of tissue and circulating long non-coding RNAs in colorectal tumors. World J Gastroenterol 25(34): 5026-5048, 2019. PMID: 31558855. DOI: 10.3748/wjg.v25.i34.5026
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wang X,
    2. Peng F,
    3. Cheng L,
    4. Yang G,
    5. Zhang D,
    6. Liu J,
    7. Chen X and
    8. Zhao S
    : Prognostic and clinicopathological role of long non-coding RNA UCA1 in various carcinomas. Oncotarget 8(17): 28373-28384, 2017. PMID: 28423704. DOI: 10.18632/oncotarget.16059
    OpenUrlCrossRefPubMed
    1. Xue M,
    2. Chen W and
    3. Li X
    : Urothelial cancer associated 1: A long noncoding RNA with a crucial role in cancer. J Cancer Res Clin Oncol 142(7): 1407-1419, 2016. PMID: 26341664. DOI: 10.1007/s00432-015-2042-y
    OpenUrlCrossRefPubMed
  8. ↵
    1. Ghafouri-Fard S and
    2. Taheri M
    : UCA1 long non-coding RNA: An update on its roles in malignant behavior of cancers. Biomed Pharmacother 120: 109459, 2019. PMID: 31585301. DOI: 10.1016/j.biopha.2019.109459
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wang Z,
    2. Wang X,
    3. Zhang D,
    4. Yu Y,
    5. Cai L and
    6. Zhang C
    : Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer. Tumour Biol 39(6): 1010428317709990, 2017. PMID: 28639914. DOI: 10.1177/1010428317709990
    OpenUrlCrossRef
  10. ↵
    1. Tao K,
    2. Yang J,
    3. Hu Y,
    4. Sun Y,
    5. Tan Z,
    6. Duan J,
    7. Zhang F,
    8. Yan H and
    9. Deng A
    : Clinical significance of urothelial carcinoma associated 1 in colon cancer. Int J Clin Exp Med 8(11): 21854-21860, 2015. PMID: 26885155
    OpenUrlPubMed
  11. ↵
    1. Liu X,
    2. Liu X,
    3. Qiao T and
    4. Chen W
    : Prognostic and clinicopathological significance of long non-coding RNA UCA1 in colorectal cancer: Results from a meta-analysis. Medicine (Baltimore) 98(48): e18031, 2019. PMID: 31770217. DOI: 10.1097/MD.0000000000018031
    OpenUrlCrossRefPubMed
  12. ↵
    1. Barbagallo C,
    2. Brex D,
    3. Caponnetto A,
    4. Cirnigliaro M,
    5. Scalia M,
    6. Magnano A,
    7. Caltabiano R,
    8. Barbagallo D,
    9. Biondi A,
    10. Cappellani A,
    11. Basile F,
    12. Di Pietro C,
    13. Purrello M and
    14. Ragusa M
    : LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA-RNA interactions. Mol Ther Nucleic Acids 12: 229-241, 2018. PMID: 30195762. DOI: 10.1016/j.omtn.2018.05.009
    OpenUrlCrossRefPubMed
  13. ↵
    1. Li Y,
    2. Zhao J,
    3. Yu S,
    4. Wang Z,
    5. He X,
    6. Su Y,
    7. Guo T,
    8. Sheng H,
    9. Chen J,
    10. Zheng Q,
    11. Li Y,
    12. Guo W,
    13. Cai X,
    14. Shi G,
    15. Wu J,
    16. Wang L,
    17. Wang P,
    18. He X and
    19. Huang S
    : Extracellular vesicles long RNA sequencing reveals abundant mRNA, circRNA, and lncRNA in human blood as potential biomarkers for cancer diagnosis. Clin Chem 65(6): 798-808, 2019. PMID: 30914410. DOI: 10.1373/clinchem.2018.301291
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Chandra Gupta S and
    2. Nandan Tripathi Y
    : Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer 140(9): 1955-1967, 2017. PMID: 27925173. DOI: 10.1002/ijc.30546
    OpenUrlCrossRefPubMed
  15. ↵
    1. Japanese Society for Cancer of the Colon and Rectum
    : Japanese classification of colorectal, appendiceal, and anal carcinoma, Ninth Edition. Tokyo: Kanehara & Co., 2018.
  16. ↵
    1. Liu FT,
    2. Dong Q,
    3. Gao H and
    4. Zhu ZM
    : The prognostic significance of UCA1 for predicting clinical outcome in patients with digestive system malignancies. Oncotarget 8(25): 40620-40632, 2017. PMID: 28380443. DOI: 10.18632/oncotarget.16534
    OpenUrlCrossRefPubMed
  17. ↵
    1. Yao F,
    2. Wang Q and
    3. Wu Q
    : The prognostic value and mechanisms of lncRNA UCA1 in human cancer. Cancer Manag Res 11: 7685-7696, 2019. PMID: 31616184. DOI: 10.2147/CMAR.S200436
    OpenUrlCrossRefPubMed
  18. ↵
    1. Gu L,
    2. Lu LS,
    3. Zhou DL and
    4. Liu ZC
    : UCA1 promotes cell proliferation and invasion of gastric cancer by targeting CREB1 sponging to miR-590-3p. Cancer Med 7(4): 1253-1263, 2018. PMID: 29516678. DOI: 10.1002/cam4.1310
    OpenUrlCrossRefPubMed
  19. ↵
    1. Qin LT,
    2. Tang RX,
    3. Lin P,
    4. Li Q,
    5. Yang H,
    6. Luo DZ,
    7. Chen G,
    8. He Y and
    9. Li P
    : Biological function of UCA1 in hepatocellular carcinoma and its clinical significance: Investigation with in vitro and meta-analysis. Pathol Res Pract 214(9): 1260-1272, 2018. PMID: 30017333. DOI: 10.1016/j.prp.2018.03.025
    OpenUrlCrossRefPubMed
  20. ↵
    1. Jiao C,
    2. Song Z,
    3. Chen J,
    4. Zhong J,
    5. Cai W,
    6. Tian S,
    7. Chen S,
    8. Yi Y and
    9. Xiao Y
    : lncRNA-UCA1 enhances cell proliferation through functioning as a ceRNA of Sox4 in esophageal cancer. Oncol Rep 36(5): 2960-2966, 2016. PMID: 27667646. DOI: 10.3892/or.2016.5121
    OpenUrlCrossRefPubMed
  21. ↵
    1. Zhang X,
    2. Gao F,
    3. Zhou L,
    4. Wang H,
    5. Shi G and
    6. Tan X
    : UCA1 regulates the growth and metastasis of pancreatic cancer by sponging miR-135a. Oncol Res 25(9): 1529-1541, 2017. PMID: 28315290. DOI: 10.3727/096504017X14888987683152
    OpenUrlCrossRef
  22. ↵
    1. Sun XD,
    2. Huan C,
    3. Qiu W,
    4. Sun DW,
    5. Shi XJ,
    6. Wang CL,
    7. Jiang C,
    8. Wang GY and
    9. Lv GY
    : Clinical significance of UCA1 to predict metastasis and poor prognosis of digestive system malignancies: A meta-analysis. Gastroenterol Res Pract 2016: 3729830, 2016. PMID: 28074092. DOI: 10.1155/2016/3729830
    OpenUrlCrossRefPubMed
  23. ↵
    1. Bian Z,
    2. Jin L,
    3. Zhang J,
    4. Yin Y,
    5. Quan C,
    6. Hu Y,
    7. Feng Y,
    8. Liu H,
    9. Fei B,
    10. Mao Y,
    11. Zhou L,
    12. Qi X,
    13. Huang S,
    14. Hua D,
    15. Xing C and
    16. Huang Z
    : LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Sci Rep 6: 23892, 2016. PMID: 27046651. DOI: 10.1038/srep23892
    OpenUrlCrossRef
  24. ↵
    1. Ni B,
    2. Yu X,
    3. Guo X,
    4. Fan X,
    5. Yang Z,
    6. Wu P,
    7. Yuan Z,
    8. Deng Y,
    9. Wang J,
    10. Chen D and
    11. Wang L
    : Increased urothelial cancer associated 1 is associated with tumor proliferation and metastasis and predicts poor prognosis in colorectal cancer. Int J Oncol 47(4): 1329-1338, 2015. PMID: 26238511. DOI: 10.3892/ijo.2015.3109
    OpenUrlCrossRefPubMed
    1. Yang X,
    2. Liu W,
    3. Xu X,
    4. Zhu J,
    5. Wu Y,
    6. Zhao K,
    7. He S,
    8. Li M,
    9. Wu Y,
    10. Zhang S,
    11. Cao J,
    12. Ye Z and
    13. Xing C
    : Downregulation of long non-coding RNA UCA1 enhances the radiosensitivity and inhibits migration via suppression of epithelial-mesenchymal transition in colorectal cancer cells. Oncol Rep 40(3): 1554-1564, 2018. PMID: 30015983. DOI: 10.3892/or.2018.6573
    OpenUrlCrossRefPubMed
  25. ↵
    1. Han Y,
    2. Yang YN,
    3. Yuan HH,
    4. Zhang TT,
    5. Sui H,
    6. Wei XL,
    7. Liu L,
    8. Huang P,
    9. Zhang WJ and
    10. Bai YX
    : UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle distribution. Pathology 46(5): 396-401, 2014. PMID: 24977734. DOI: 10.1097/PAT.0000000000000125
    OpenUrlCrossRefPubMed
  26. ↵
    1. Markowitz SD and
    2. Bertagnolli MM
    : Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361(25): 2449-2460, 2009. PMID: 20018966. DOI: 10.1056/NEJMra0804588
    OpenUrlCrossRefPubMed
  27. ↵
    1. Molina-Cerrillo J,
    2. San Román M,
    3. Pozas J,
    4. Alonso-Gordoa T,
    5. Pozas M,
    6. Conde E,
    7. Rosas M,
    8. Grande E,
    9. García-Bermejo ML and
    10. Carrato A
    : BRAF mutated colorectal cancer: New treatment approaches. cancers (Basel) 12(6): 2020. PMID: 32545884. DOI: 10.3390/cancers12061571
    OpenUrlCrossRefPubMed
  28. ↵
    1. Tie J,
    2. Gibbs P,
    3. Lipton L,
    4. Christie M,
    5. Jorissen RN,
    6. Burgess AW,
    7. Croxford M,
    8. Jones I,
    9. Langland R,
    10. Kosmider S,
    11. McKay D,
    12. Bollag G,
    13. Nolop K,
    14. Sieber OM and
    15. Desai J
    : Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 128(9): 2075-2084, 2011. PMID: 20635392. DOI: 10.1002/ijc.25555
    OpenUrlCrossRefPubMed
  29. ↵
    1. Artale S,
    2. Sartore-Bianchi A,
    3. Veronese SM,
    4. Gambi V,
    5. Sarnataro CS,
    6. Gambacorta M,
    7. Lauricella C and
    8. Siena S
    : Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26(25): 4217-4219, 2008. PMID: 18757341. DOI: 10.1200/JCO.2008.18.7286
    OpenUrlFREE Full Text
  30. ↵
    1. Vakiani E,
    2. Janakiraman M,
    3. Shen R,
    4. Sinha R,
    5. Zeng Z,
    6. Shia J,
    7. Cercek A,
    8. Kemeny N,
    9. D’Angelica M,
    10. Viale A,
    11. Heguy A,
    12. Paty P,
    13. Chan TA,
    14. Saltz LB,
    15. Weiser M and
    16. Solit DB
    : Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 30(24): 2956-2962, 2012. PMID: 22665543. DOI: 10.1200/JCO.2011.38.2994
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lankenau MA,
    2. Patel R,
    3. Liyanarachchi S,
    4. Maharry SE,
    5. Hoag KW,
    6. Duggan M,
    7. Walker CJ,
    8. Markowitz J,
    9. Carson WE 3rd.,
    10. Eisfeld AK and
    11. de la Chapelle A
    : MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies. Proc Natl Acad Sci USA 112(49): E6744-E6751, 2015. PMID: 26582795. DOI: 10.1073/pnas.152039011
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (4)
Anticancer Research
Vol. 41, Issue 4
April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status
TOMOHITO MAEDA, HIROTAKA KONISHI, WATARU TAKAKI, KAZUYA TAKABATAKE, DAIKI MATSUBARA, KATSUTOSHI SHODA, TOMOHIRO ARITA, HIROKI SHIMIZU, SHUHEI KOMATSU, ATSUSHI SHIOZAKI, YOSHIAKI KURIU, EIGO OTSUJI
Anticancer Research Apr 2021, 41 (4) 1761-1769; DOI: 10.21873/anticanres.14941

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Significance of Plasma UCA1 for Predicting Colorectal Cancer and BRAF Mutation Status
TOMOHITO MAEDA, HIROTAKA KONISHI, WATARU TAKAKI, KAZUYA TAKABATAKE, DAIKI MATSUBARA, KATSUTOSHI SHODA, TOMOHIRO ARITA, HIROKI SHIMIZU, SHUHEI KOMATSU, ATSUSHI SHIOZAKI, YOSHIAKI KURIU, EIGO OTSUJI
Anticancer Research Apr 2021, 41 (4) 1761-1769; DOI: 10.21873/anticanres.14941
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Enhanced DNA Double-strand Break Induction by Carbon Ions Under Intratumoral Hypoxia
  • C-myc Oncogene Numerical Imbalances Analysis in Laryngeal Squamous Cell Carcinoma
  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
Show more Experimental Studies

Similar Articles

Keywords

  • UCA1
  • colorectal cancer
  • BRAF mutation
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire